{"disease":{"id":"her2-positive-advanced-gastric-cancer-or-gastroesophageal-junction-adenocarcinoma","name":"her2 positive advanced gastric cancer or gastroesophageal junction adenocarcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06123494","title":"SHR-A1811 for Subjects With Her2-positive Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on or After First-line Anti-HER2 Therapy-containing Regimen","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":360,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}